SCCMPod-564 CCE: Endotoxin Activity and Precision Medicine in Septic Shock

The podcast explores the concept of high endotoxin activity as a potential endotype for septic shock, revisiting earlier interests in endotoxin's role in sepsis. Dr. John A. Kellum, Chief Medical Officer for Spectral Medical, discusses the heterogeneity in septic shock outcomes and the potential of precision medicine to target specific subphenotypes. The conversation highlights the four phenotypes (alpha, beta, gamma, and delta) and their differing mortality risks and organ dysfunction patterns. The discussion covers the utility of the endotoxin activity assay (EAA) in identifying patients at high risk for endotoxic septic shock and the potential for targeted therapies like polymyxin B hemoabsorption. The need for better diagnostics and a genetic predisposition to severe host response to endotoxin are also addressed.